Chimerix founder to speak at Institute of Medicine Workshop

Chimerix, Inc.'s founder and CEO George Painter, Ph.D., will join with representatives from government, industry and academia in an Institute of Medicine Workshop that will focus on improving innovation around the discovery and development of new products needed to undertake medical countermeasures when responding to public health emergencies.

The workshop, titled "The Public Health Emergency Medical Countermeasures Enterprise: Innovative Strategies to Enhance Products from Discovery Through Approval," is being held this week at The National Academy of Sciences Building in Washington, D.C.

The goal of the workshop is to examine federal policies and activities that pertain to the discovery and approval of products that are considered integral to the undertaking of medical countermeasures for responding to public health emergencies, including bioterrorist attacks, that could overwhelm existing public health and medical systems.

Dr. Painter will take part in a panel titled "Opportunities for enhancing translation of basic science: models to improve innovation that responds to national priorities." The panel was convened as a method to address the procurement and improvement of scientific innovation based on an assessment of national biodefense priorities.

Chimerix, a biotechnology company that develops orally-available antiviral therapeutics, is currently developing CMX001 as a biodefense countermeasure against the release of smallpox.